These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35784107)

  • 41. New-onset hyperglycaemia and prolonged systemic corticosteroids therapy in mild COVID-19 patients as major risk factors for invasive mucormycosis: a preliminary study.
    Khichar S; Samantaray S; Kumar D; Mobarsa V; Jain V; Sharma V; Soni K; Choudhury B; Goyal A; Shankar Meena D; Srinivasan S; Dutt N; Bhardwaj P; Agarwal A; Kumar Garg M; Misra S
    Curr Med Mycol; 2021 Sep; 7(3):22-28. PubMed ID: 35528622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COVID-19 associated mucormycosis - An emerging threat.
    Chao CM; Lai CC; Yu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India.
    Singh P; Sharma K; Singh P; Bhargava A; Negi SS; Sharma P; Bhise M; Tripathi MK; Jindal A; Nagarkar NM
    Microb Pathog; 2022 Mar; 164():105404. PubMed ID: 35065253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mucor in a Viral Land: A Tale of Two Pathogens.
    Sen M; Lahane S; Lahane TP; Parekh R; Honavar SG
    Indian J Ophthalmol; 2021 Feb; 69(2):244-252. PubMed ID: 33463566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mucormycosis in COVID-19: A systematic review of literature.
    Nagalli S; Kikkeri NS
    Infez Med; 2021; 29(4):504-512. PubMed ID: 35146358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
    Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
    Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management.
    Rudrabhatla PK; Reghukumar A; Thomas SV
    Acta Neurol Belg; 2022 Apr; 122(2):273-280. PubMed ID: 34820787
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India.
    Singh AK; Singh R; Joshi SR; Misra A
    Diabetes Metab Syndr; 2021; 15(4):102146. PubMed ID: 34192610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study.
    Khan M; Khan H; Khan S; Nawaz M
    J Med Microbiol; 2020 Aug; 69(8):1114-1123. PubMed ID: 32783802
    [No Abstract]   [Full Text] [Related]  

  • 50. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis.
    Moorthy A; Gaikwad R; Krishna S; Hegde R; Tripathi KK; Kale PG; Rao PS; Haldipur D; Bonanthaya K
    J Maxillofac Oral Surg; 2021 Sep; 20(3):418-425. PubMed ID: 33716414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. As the virus sowed, the fungus reaped! A comparative analysis of the clinico-epidemiological characteristics of rhino-orbital mucormycosis before and during COVID-19 pandemic.
    Muraleedharan M; Panda NK; Angrish P; Arora K; Patro SK; Bansal S; Chakrabarti A; Rudramurthy SM; Bakshi J; Mohindra S; Gupta R; Virk RS; Verma RK; Ramavat AS; Nayak G
    Mycoses; 2022 May; 65(5):567-576. PubMed ID: 35289000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
    Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
    Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Absence of Case of Mucormycosis (March 2020-May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit.
    Mulakavalupil B; Vaity C; Joshi S; Misra A; Pandit RA
    Diabetes Metab Syndr; 2021; 15(4):102169. PubMed ID: 34198110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucormycosis in COVID-19 Patients: A Case-Control Study.
    Pandit AK; Tangri P; Misra S; Srivastava MVP; Bhatnagar S; Thakar A; Sikka K; Panda S; Vishnu VY; Singh RK; Das A; Radhakrishnan DM; Srivastava AK; Subramaniam R; Trikha A; Agarwal A; Rajan R; Upadhyay V; Parikipandla S; Singh A; Kairo A
    Microorganisms; 2022 Jun; 10(6):. PubMed ID: 35744726
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients.
    Bansal SB; Rana A; Babras M; Yadav D; Jha P; Jain M; Sethi SK
    Transpl Infect Dis; 2022 Apr; 24(2):e13777. PubMed ID: 34932870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinico-demographic profile & hospital outcomes of COVID-19 patients admitted at a tertiary care centre in north India.
    Mohan A; Tiwari P; Bhatnagar S; Patel A; Maurya A; Dar L; Pahuja S; Garg R; Gupta N; Sahoo B; Gupta R; Meena VP; Vig S; Pandit A; Mittal S; Madan K; Hadda V; Dwivedi T; Choudhary A; Brijwal M; Soneja M; Guleria R; Ratre B; Kumar B; Bhopale S; Panda S; Singh AR; Singh S; Wundavalli L
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):61-69. PubMed ID: 32773414
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Demographic & clinical profile of patients with COVID-19 at a tertiary care hospital in north India.
    Soni SL; Kajal K; Yaddanapudi LN; Malhotra P; Puri GD; Bhalla A; Singh MP; Sehgal IS; Koushal V; Varma N; Biswal M; Lakshmi PVM; Sharma S; Suri V; Deepy Z; Ram S; Yadav J; Pandey N; Sharma P; Malik N; Goyal K; Mehra A; Sahoo S; Mohindra R; Francis J; Bhargava M; Singla K; Babu P; Verma A; Khaire NS; Guru RR
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):115-125. PubMed ID: 33818468
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post COVID-19 Mucormycosis-The Horizon.
    J JAT; Reddy LS
    Indian J Otolaryngol Head Neck Surg; 2023 Jun; 75(2):517-522. PubMed ID: 36540726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathogenetic factors fanning the flames of COVID-19 to cause rhino-orbito-cerebral mucormycosis: An observational study.
    Reddy YM; Yeduguri S; Reddy N VS; Parida S; Kamatham SN; Pidaparthi L; Jaiswal SK; Sadhvani B; Tourani V; Kumar S; Challa S; Murthy JM
    J Mycol Med; 2022 May; 32(2):101252. PubMed ID: 35134736
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19-associated mucormycosis: Preliminary report from a tertiary eye care centre.
    Walia S; Bhaisare V; Rawat P; Kori N; Sharma M; Gupta N; Urdhwareshwar S; Thakur S; Arya N
    Indian J Ophthalmol; 2021 Dec; 69(12):3685-3689. PubMed ID: 34827023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.